If You Had Bought Immunomedics (NASDAQ:IMMU) Shares Five Years Ago You’d Have Made 332%

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Immunomedics, Inc. (NASDAQ:IMMU) shareholders have seen the share price descend 21% over the month. But that doesn’t undermine the fantastic longer term performance (measured over five years). In that time, the share price has soared some 332% higher! So it might be that some shareholders are taking profits after good performance. Of course what matters most is whether the business can improve itself sustainably, thus justifying a higher price.

See our latest analysis for Immunomedics

With just US$1,465,996 worth of revenue in twelve months, we don’t think the market considers Immunomedics to have proven its business plan. As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. For example, they may be hoping that Immunomedics comes up with a great new treatment, before it runs out of money.

As a general rule, if a company doesn’t have much revenue, and it loses money, then it is a high risk investment. There is almost always a chance they will need to raise more capital, and their progress – and share price – will dictate how dilutive that is to current holders. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized). Immunomedics has already given some investors a taste of the sweet gains that high risk investing can generate, if your timing is right.

Immunomedics had net cash of just US$236m when it last reported (December 2018). So if it has not already moved to replenish reserves, we think the near-term chances of a capital raising event are pretty high. It’s a testament to the popularity of the business plan that the share price gained 34% per year, over 5 years, despite the weak balance sheet. The image below shows how Immunomedics’s balance sheet has changed over time; if you want to see the precise values, simply click on the image.

NasdaqGM:IMMU Historical Debt, May 8th 2019
NasdaqGM:IMMU Historical Debt, May 8th 2019

In reality it’s hard to have much certainty when valuing a business that has neither revenue or profit. Given that situation, many of the best investors like to check if insiders have been buying shares. If they are buying a significant amount of shares, that’s certainly a good thing. You can click here to see if there are insiders buying.

A Different Perspective

Immunomedics shareholders are down 23% for the year, but the market itself is up 8.1%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 34% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.